Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1618-1622

  Khan, G ^a   Golshayan, A ^b   Elson, P ^b   Wood, L ^b   Garcia, J ^b   Bukowski, R ^b   Rini, B ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Renal cell carcinoma; Renal insufficiency; Sorafenib; Sunitinib; VEGF targeted therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; PYRROLES; RENAL INSUFFICIENCY;

EID: 77955248323     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp603     Document Type: Article

References (27)

1. O'Brien MF, Russo P, Motzer RJ. Sunitinib therapy in renal cell carcinoma. BJU Int 2008; 101(11): 1339-1342.
2. Gunaratnam L, Morley M, Franovic A et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 2003; 278(45): 44966-44974.
3. Kenck C, Wilhelm M, Bugert P et al. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996; 179(2): 157-161.
4. Ronnen EA, Kondagunta GV, Ginsberg MS et al. Long-term response with sunitinib for metastatic renal cell carcinoma. Urology 2006; 68(3): 672. e19,672.e20.
5. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2(5): 471-478.
6. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9(1): 327-337.
7. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101(9): 3597-3605.
8. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20(8): 757-766.
9. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91(10): 4070-4076.
10. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
11. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5): 965-972.
12. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16(10): 1688-1694.
13. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11(15): 5472-5480.
14. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92(10): 1855-1861.
15. Fiedler W, Serve H, Dohner H et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105(3): 986-993.
16. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24(1): 25-35.
17. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(1): 16-24.
18. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295(21): 2516-2524.
19. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
21. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26(1): 127-131.
22. Parsa VK, Heilbrun L, Smith D et al. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. In Genitourinaly Cancer Symposium, Orlando, 2008. (Abstr 365).
23. Billemont B, Thibault F, Ropert S et al. Association between acute severe renal toxicity (ASRT) and survival in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib. In Genitourinary Cancers Symposium, Orlando, 2009. (Abstr 307).
24. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48(1): 9-17.
25. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet 1992; 340(8823): 807-810.
26. Shirasaki Y, Tsushima T, Saika T et al. Kidney function after nephrectomy for renal cell carcinoma. Urology 2004; 64(1): 43-47.
27. Bello C, Toh M, Garrett M. Pharmacokinetics of sunitinib in patients with severe renal impairment or end-stage renal disease on hemodialysis. Pfizer Global Res Develop, European Society of Medical Oncology Annual Meeting, Stockholm, Sweden, 2008 (Abstr 889).